The main objective of this article is intended to help clinicians determine if a tumor mutation is potentially treatable with a marketed or investigational drug or biologic product and to offer guidance on how to access the product of interest.Targeted cancer therapies are drugs and biologics designed to affect cancer cell growth by blocking or interfering with specific molecular pathways in the cancer cell.
Although the US Food and Drug Administration (FDA) has approved more than 80 targeted therapy agents (many of which have multiple indications across cancer types),5 these agents are still directed against a limited number of genomic or other molecular targets, many of which occur at a low frequency in solid tumors of adults. The Association for Molecular Pathology, ASCO, and the College of American Pathologists released joint consensus recommendations in 2017 to guide clinicians in interpreting genomic test reports.As of May 2018, the federal government enables patients and clinicians to pursue access directly from manufacturers, bypassing the FDA safeguards and assistance.
So a tumor mutations possibility cannot be just decided by seeing the looks of it. An oncologist must have a complete detailed knowledge of this point to provide the best he can.
https://ascopubs.org/doi/full/10.1200/JOP.19.00262
